Singapore, Oct. 6 -- SK pharmteco, a subsidiary of SK Inc., the strategic investment company for SK Group, South Korea's second-largest conglomerate, has announced a comprehensive five-year, more than $200 million investment plan to expand and upgrade its US development and manufacturing infrastructure across small molecules and peptides.

This continues SK pharmteco's global growth strategy, complementing the company's recent $6 million investment in its California facility to boost peptide development, the opening of two advanced manufacturing facilities at its Ireland campus to scale up the site's capability to deliver both large-scale commercial small molecules and ultra-high-potency active pharmaceutical ingredients (HPAPIs), and its...